อาการไม่พึงประสงค์ทางผิวหนังจากการรักษามะเร็ง :  มุมมองทางคลินิกในบริบทประเทศไทย

Benjaporn Srisantithum; Panuch Eiamprapaporn

Authors

Benjaporn Srisantithum Thammasat University Hospital
Panuch Eiamprapaporn Thammasat University Hospital

Keywords:

Cancer, Dermatological adverse events, Cancer therapy, Skin care, Thailand

Abstract

Cancer treatments, including chemotherapy, targeted therapy, immunotherapy, and radiotherapy, frequently induce dermatological adverse events (DAEs) that significantly impact patients' quality of life and treatment adherence. This review article, tailored for the Thai context, aims to provide a comprehensive overview of common DAEs, their prevention and management, specific considerations for prevalent cancers (lung, breast, colon), and practical guidance on daily skin care, hair management, and evidence-based supplements. The article highlights the relevance of these toxicities to common cancer types encountered in Thailand and addresses frequently asked patient questions regarding skincare routines, hair dyeing, hair implantation, and the use of vitamins or supplements, emphasizing evidence levels from PubMed or Scopus. Proactive management and a multidisciplinary approach involving both oncologists and dermatologists are crucial for mitigating DAEs and optimizing patient outcomes in cancer care.

References

Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernández-Peñas P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157-70.

Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy for the treatment of renal cell carcinoma. Eur J Cancer. 2020;136:52-68.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12-25.

Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787-94.

Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol. 2015;72(4):656-67.

Imsamran W, Pattatang A, Supaattagorn P, Chiawiriyabunya I, Namthaisong K, Wongsena M, et al. Cancer in Thailand Vol. IX, 2013-2015. Bangkok: New Thammada Press; 2018.

Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and subnational population-based incidence of cancer in Thailand: assessing cancers with the highest burdens. Cancers (Basel). 2017;9(8):108.

Thongprasert S, Sriplung H, Boonpipattanapong T, Chewaskulyong B, Atjimakul T, Kanjanavirojkul N, et al. The current status of cancer care and management in Thailand. JCO Glob Oncol. 2021;7:64-72.

Sibaud V, Delord JP, Chevreau C. Dermatological adverse events of immune checkpoint inhibitors: a summarized overview. Curr Opin Oncol. 2019;31(4):319-24.

Munhoz RR, Postow MA. Recent advances in understanding and managing checkpoint inhibitor dermatologic adverse events. JAMA Oncol. 2018;4(11):1457-58.

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313-18.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-68.

Ratanapakorn T, Prasitthipayong A, Chewaskulyong B. Traditional medicine usage among Thai patients with cancer: a prospective cross-sectional survey in Thailand. BMC Complement Med Ther. 2020;20(1):331.

Dreno B, Khosrotehrani K, De Barros Silva G, Ramam M, Abreu Velez AM, Rosmarin D, et al. The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus. Support Care Cancer. 2023;31(11):672.

Alcalá Pérez D, Acosta Madiedo AS, Andreani S, Arenas-Soto CM, Ariza-Cadena E, Asz-Sigall D, et al. Latin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors. J Drugs Dermatol. 2025;24(3):262.

Ladwa R, Fogarty G, Chen P, Fernandez-Peñas P. Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective. Cancers (Basel). 2024;16(13):2526.

Decker GM. Use of hair dyes following chemotherapy. Clin J Oncol Nurs. 2004;8(1):89-9.

Gisondi P, Girolomoni G. Skin moisturization for xerosis related to targeted anticancer therapies. J Am Acad Dermatol. 2015;73(1):e33 e34.

Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, et al; D TORCH Trial Investigators. Topical diclofenac for prevention of capecitabine associated hand foot syndrome: a double blind randomized controlled trial. J Clin Oncol. 2024;42(15):1821 1829.

Rosenthal A, Israilevich R, Moy R. Management of acute radiation dermatitis: A review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019 Aug;81(2):558-567.